lenvatinib as up-front therapy for unresectable hcc
Published 5 years ago • 3.9K plays • Length 7:37Download video MP4
Download video MP3
Similar videos
-
6:54
upfront lenvatinib in unresectable hcc
-
8:55
implication of upfront lenvatinib in hcc
-
1:41
dr. armaghany on frontline sorafenib versus lenvatinib in unresectable hcc
-
2:56
dr. finn on role of lenvatinib in hcc treatment paradigm
-
4:16
frontline therapy for hcc: optimizing treatment selection
-
1:22
dr. cheng on phase iii findings of lenvatinib in hcc
-
1:40
comparing sorafenib and lenvatinib for the frontline treatment of advanced hcc
-
5:59
frontline lenvatinib vs sorafenib in hcc
-
5:19
lenvatinib remains standard of care for first-line therapy in advanced hepatocellular carcinoma
-
1:24
phase iii findings for lenvatinib in hcc
-
6:53
sequencing in dtc: lenvatinib and sorafenib
-
4:46
liver cancer updates
-
4:54
reflect trial: frontline lenvatinib’s value in hcc
-
0:48
dr. cabanillas on lenvatinib as first-line therapy for patients with dtc
-
1:33
adverse events inform treatment decisions in hcc for frontline lenvatinib versus sorafenib
-
3:06
jeff evans, asco 2018 – lenvatinib plus pembrolizumab in hepatocellular carcinoma
-
5:39
hcc: criteria for resection and adjuvant therapy
-
1:43
treatment for advanced-stage hcc
-
7:24
practical considerations for using lenvatinib in hcc